Literature DB >> 25312890

Sustained complete remission of primary effusion lymphoma with adjunctive ganciclovir treatment in an HIV-positive patient.

Rui Pereira1, Joana Carvalho1, Catarina Patrício1, Pedro Farinha2.   

Abstract

Primary effusion lymphoma (PEL) is one of the least common of the AIDS-related lymphomas, accounting for less than 1-4% of cases. Clinical manifestations depend on the extent and distribution of disease and, as in the majority of patients no detectable mass lesion is found, symptoms are related to fluid accumulation, dyspnoea (pleural or pericardial effusions), abdominal distension (ascites) or joint swelling. The median survival after diagnosis, even with aggressive chemotherapy, remains poor and remissions are often of short duration. We present the case of a 31-year-old man with AIDS and diagnosis of PEL, in whom sustained and complete remission of the tumour was achieved with adjunctive ganciclovir therapy. Since the disease is so uncommon, there is a paucity of data to guide the treatment of these patients; ganciclovir might be a potential antiviral therapeutic option, as demonstrated by the 2-year remission achieved in our patient. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25312890      PMCID: PMC4195214          DOI: 10.1136/bcr-2014-204533

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

1.  Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group.

Authors:  D F Martin; B D Kuppermann; R A Wolitz; A G Palestine; H Li; C A Robinson
Journal:  N Engl J Med       Date:  1999-04-08       Impact factor: 91.245

2.  Prognosis in primary effusion lymphoma is associated with the number of body cavities involved.

Authors:  Jorge J Castillo; Helen Shum; Majid Lahijani; Eric S Winer; James N Butera
Journal:  Leuk Lymphoma       Date:  2012-06-13

3.  A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy.

Authors:  T R Halfdanarson; S N Markovic; U Kalokhe; M Luppi
Journal:  Ann Oncol       Date:  2006-06-09       Impact factor: 32.976

4.  Successful secondary prophylaxis for primary effusion lymphoma with human herpesvirus 8 therapy.

Authors:  Nancy F Crum-Cianflone; Mark R Wallace; David Looney
Journal:  AIDS       Date:  2006-07-13       Impact factor: 4.177

5.  CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.

Authors:  Shruti Bhatt; Brittany M Ashlock; Yasodha Natkunam; Victoria Sujoy; Jennifer Rose Chapman; Juan Carlos Ramos; Enrique A Mesri; Izidore S Lossos
Journal:  Blood       Date:  2013-07-09       Impact factor: 22.113

Review 6.  The use of antiviral drugs in the prevention and treatment of Kaposi sarcoma, multicentric Castleman disease and primary effusion lymphoma.

Authors:  C Casper; A Wald
Journal:  Curr Top Microbiol Immunol       Date:  2007       Impact factor: 4.291

7.  Novel association of haemophagocytic syndrome with Kaposi's sarcoma-associated herpesvirus-related primary effusion lymphoma.

Authors:  R D Pastore; A Chadburn; C Kripas; E J Schattner
Journal:  Br J Haematol       Date:  2000-12       Impact factor: 6.998

8.  Is valganciclovir really effective in primary effusion lymphoma: case report of an HIV(-) EBV(-) HHV8(+) patient.

Authors:  Murat Ozbalak; Ilyas Tokatlı; Metin Özdemirli; Tülay Tecimer; Muhlis Cem Ar; Serdar Örnek; Aykut Koroglu; Yahya Laleli; Burhan Ferhanoglu
Journal:  Eur J Haematol       Date:  2013-08-17       Impact factor: 2.997

9.  Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study.

Authors:  Cecelia Simonelli; Michele Spina; Roberta Cinelli; Renato Talamini; Rosamaria Tedeschi; Annunziata Gloghini; Emanuela Vaccher; Antonio Carbone; Umberto Tirelli
Journal:  J Clin Oncol       Date:  2003-11-01       Impact factor: 44.544

10.  Primary effusion lymphoma involving three body cavities.

Authors:  Fadi Brimo; Gizelle Popradi; René P Michel; Manon Auger
Journal:  Cytojournal       Date:  2009-10-09       Impact factor: 2.091

View more
  3 in total

1.  A unique case of primary effusion lymphoma-like lymphoma showing disappearance and recurrence of the body cavity effusion.

Authors:  Chikahiko Koeda; Takashi Sato; Yuki Matsumoto; Yuta Usui; Fusanori Kunugida; Muneyoshi Ogawa
Journal:  J Gen Fam Med       Date:  2017-03-21

2.  [Primary effusion lymphoma in a HIV-negative patient: case report and literatures review].

Authors:  Y F Song; H Liu; J F Bai; H X Ke; J T Li; T Wang; Y Z Yang; J J Yin; R Feng
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-08-14

Review 3.  Human γ-Herpesvirus Infection, Tumorigenesis, and Immune Control in Mice with Reconstituted Human Immune System Components.

Authors:  Christian Münz
Journal:  Front Immunol       Date:  2018-02-12       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.